



The following applies to BRTP / Rapid Hereditary Breast Cancer Treatment Decision Panel. Testing is performed to evaluate for the presence of variants in coding regions and extending to +/- 10 base pairs of adjacent intronic sequence on either side of the coding exons of the genes analyzed. In addition, the analysis will cover select noncoding variants. Next-generation sequencing and/or a polymerase chain reaction-based quantitative method is performed to test for the presence of copy number variants in the genes analyzed. Confirmation of select reportable variants may be performed by alternate methodologies based on internal laboratory criteria.

This list is current from June 2023 to the present. This document is intended to highlight additional evaluations for variants of high clinical interest as well as technical limitations. However, this document does not comprehensively reflect all genomic regions covered by this test. For questions regarding transcripts, genes or regions covered, contact the laboratory at 800-533-1710.

Genomic Build: GRCh37 (hg19) unless otherwise specified

<b>Gene</b>	<b>Reference Transcript</b>	<b>Additional Evaluations</b>	<b>Technical Limitations</b>
<i>ATM</i>	NM_000051.3	-	-
<i>BRCA1</i>	NM_007294.4	+/- 20 base pairs of adjacent intronic sequence on either side of the coding exons	-
<i>BRCA2</i>	NM_000059.3	+/- 20 base pairs of adjacent intronic sequence on either side of the coding exons	-
<i>CDH1</i>	NM_004360.5	-	-
<i>CHEK2</i>	NM_007194.4	-	-
<i>PALB2</i>	NM_024675.4	-	-
<i>PTEN</i>	NM_000314.8	Promoter: c.-1302 to c.-589	-
<i>RAD51C</i>	NM_058216.3	-	-
<i>RAD51D</i>	NM_002878.3	-	-
<i>STK11</i>	NM_000455.5	-	-
<i>TP53</i>	NM_000546.5	-	-